Genmab A/S (GMAB)
35.30
+0.47
(+1.35%)
USD |
NASDAQ |
Sep 25, 16:00
35.30
0.00 (0.00%)
After-Hours: 19:59
Genmab Research and Development Expense (Annual) : 1.564B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 1.564B |
| December 31, 2024 | 1.374B |
| December 31, 2023 | 1.079B |
| December 31, 2022 | 755.23M |
| December 31, 2021 | 636.37M |
| December 31, 2020 | 449.13M |
| December 31, 2019 | 337.30M |
| December 31, 2018 | 212.92M |
| December 31, 2017 | 122.06M |
| December 31, 2016 | 92.13M |
| December 31, 2015 | 67.81M |
| December 31, 2014 | 87.86M |
| December 31, 2013 | 91.95M |
| Date | Value |
|---|---|
| December 31, 2012 | 90.17M |
| December 31, 2011 | 96.65M |
| December 31, 2010 | 100.42M |
| December 31, 2009 | 171.59M |
| December 31, 2008 | 245.89M |
| December 31, 2007 | 154.79M |
| December 31, 2006 | 84.67M |
| December 31, 2005 | 68.98M |
| December 31, 2004 | 55.43M |
| December 31, 2003 | 44.39M |
| December 31, 2002 | 45.19M |
| December 31, 2001 | 19.26M |
| December 31, 2000 | 5.166M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| AbbVie, Inc. | 8.249B |
| Ascendis Pharma A/S | 333.10M |
| Zealand Pharma A/S | 239.48M |
| Bavarian Nordic A/S | 117.03M |
| Evaxion AS | 9.691M |